Agilent Technologies Inc
NYSE:A
Net Margin
Agilent Technologies Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31B USD |
19%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
974.7B USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
148.6B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
132.1B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
179.2B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
23.9B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.2B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.6B EUR |
7%
|
|
| US |
|
Waters Corp
NYSE:WAT
|
20.6B USD |
22%
|
Agilent Technologies Inc
Glance View
Agilent Technologies Inc., a spin-off from Hewlett-Packard in 1999, has cultivated a niche in the vibrant landscape of the life sciences, diagnostics, and applied chemical markets. This California-based company, born from the legacy of one of Silicon Valley’s pioneers, has carved out its identity by providing sophisticated analytical instrumentation, software, services, and consumables for a wide range of applications. Agilent's businesses are stitched together by an underlying technology expertise, which forms the bedrock for its product lines that serve an increasing demand for precise and reliable analytical measurements. From cutting-edge liquid chromatography to mass spectrometry and genetic analysis systems, Agilent's offerings are geared towards supporting research and quality control processes across various industries, including pharmaceuticals, food safety, and environmental testing. The company's commitment to innovation and quality has consistently positioned it as a trusted partner in advancing the capabilities of laboratories worldwide. Agilent's revenue generation hinges on a strategic blend of product sales and services. The core of its business model revolves around not just selling instruments, but also establishing long-term relationships through service agreements, maintenance, and training. This recurring service revenue complements the sale of consumables and parts required for the operation of their sophisticated instruments. Additionally, Agilent has strategically expanded its footprint in the diagnostics market, providing instruments and reagents used in pathology laboratories, further diversifying its income streams. With a deliberate focus on high-growth areas, including genomics and cancer diagnostics, Agilent continues to leverage its technological prowess and industry expertise to capture market share in sectors that are inherently driven by the necessity for innovation and regulatory compliance. Through an intricate balance of hardware sales and consistent after-sale support, Agilent steadily maintains its role as a formidable player in the analytical instrumentation sector.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Agilent Technologies Inc's most recent financial statements, the company has Net Margin of 19.3%.
You don't have any saved screeners yet